Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

开始日期2024-05-01

申办/合作机构

The George Institute for Global Health

[+2]

NCT06403267 / Not yet recruiting临床2期

A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).
This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well.

开始日期2024-05-01

申办/合作机构

NoNO, Inc.

NCT05636306 / Completed临床1期

A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.
Participants will be administered a single intravenous dose of NoNO-42 or placebo.
Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28.

开始日期2022-11-22

申办/合作机构

NoNO, Inc.

100 项与 NoNO-42 相关的临床结果

登录后查看更多信息

100 项与 NoNO-42 相关的转化医学

登录后查看更多信息

100 项与 NoNO-42 相关的专利（医药）

登录后查看更多信息

100 项与 NoNO-42 相关的药物交易

登录后查看更多信息